Key result
The decision to maintain or discontinue antiplatelet therapy during noncardiac surgery requires a personalized multidisciplinary approach balancing ischemic and bleeding risks.
Answers are grounded in this paper and cite their sources.
This review provides a personalized algorithm for managing antiplatelet therapy in patients with ischemic heart disease undergoing noncardiac surgery, balancing the risks of surgical bleeding and ischemic events.
.. 8 4 2020 () . . . .
No takes yet. Share an insight, caveat, or question.
Chomakhidze et al. (2020) conducted a review in Ischemic heart disease. Antiplatelet therapy was evaluated. The decision to maintain or discontinue antiplatelet therapy during noncardiac surgery requires a personalized multidisciplinary approach balancing ischemic and bleeding risks.
Synapse has enriched 10 related papers. Consider them for comparative context: